Among pharmacological therapies evaluated for CRHM management, SGLT2 inhibitors have consistently demonstrated the most robust and broad cardiovascular benefits, particularly in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Here, SLC5A2 is linked to diabetes mellitus.